- Home
- TEL vs IQV Comparison
TEL vs IQV Comparison
Compare TEL & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEL
- IQV
- Stock Information
- Founded
- TEL 1941
- IQV 1982
- Country
- TEL Ireland
- IQV United States
- Employees
- TEL N/A
- IQV N/A
- Industry
- TEL Industrial Machinery/Components
- IQV Biotechnology: Commercial Physical & Biological Resarch
- Sector
- TEL Technology
- IQV Health Care
- Exchange
- TEL Nasdaq
- IQV Nasdaq
- Market Cap
- TEL 43.5B
- IQV 35.7B
- IPO Year
- TEL 2007
- IQV 2013
- Fundamental
- Price
- TEL $140.92
- IQV $203.24
- Analyst Decision
- TEL Buy
- IQV Strong Buy
- Analyst Count
- TEL 11
- IQV 17
- Target Price
- TEL $159.36
- IQV $255.88
- AVG Volume (30 Days)
- TEL 1.5M
- IQV 1.2M
- Earning Date
- TEL 01-22-2025
- IQV 02-12-2025
- Dividend Yield
- TEL 1.84%
- IQV N/A
- EPS Growth
- TEL 71.45
- IQV 27.98
- EPS
- TEL 10.34
- IQV 7.62
- Revenue
- TEL $15,845,000,000.00
- IQV $15,315,000,000.00
- Revenue This Year
- TEL $5.31
- IQV $3.11
- Revenue Next Year
- TEL $6.72
- IQV $4.58
- P/E Ratio
- TEL $13.63
- IQV $26.68
- Revenue Growth
- TEL N/A
- IQV 3.10
- 52 Week Low
- TEL $128.52
- IQV $187.62
- 52 Week High
- TEL $159.98
- IQV $261.73
- Technical
- Relative Strength Index (RSI)
- TEL 35.41
- IQV 54.80
- Support Level
- TEL $139.80
- IQV $198.34
- Resistance Level
- TEL $146.45
- IQV $199.27
- Average True Range (ATR)
- TEL 2.93
- IQV 4.70
- MACD
- TEL -0.15
- IQV 1.21
- Stochastic Oscillator
- TEL 11.73
- IQV 76.23
About TEL TE Connectivity Ltd. New Switzerland Registered Shares
TE Connectivity is the largest electrical connector supplier in the world, supplying interconnect and sensor solutions to the transportation, industrial, and communications markets. With operations in 150 countries and over 500,000 stock-keeping units, TE has a broad portfolio that forms the electrical architecture of its end customers' cutting-edge innovations.
About IQV IQVIA Holdings Inc.
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.